bioAffinity Technologies reported Q2 2026 CyPath Lung sales growth of over 200% to a new record driven by increased physician adoption and repeat utilization. The acceleration in test volume underscores a strong commercial trajectory for the company's non-invasive lung cancer diagnostics.